Glioblastoma Patient and Caregiver Perspectives of Treatment Side-Effects and Information Provision

Chemoradiotherapy treatment for glioblastoma causes acute and long-term toxicities, negatively impacting quality of life. Patients require evidence-based, yet understandable information regarding treatment-induced toxicities to increase preparedness for treatment. A repeat cross-sectional, qualitati...

Full description

Saved in:
Bibliographic Details
Main Authors: Sharon Fernandez BSc, PGCert, MSc, Susan C Short MBBS, BSc, MRCP, FRCR, PhD, Florien Boele BSc, MSc, PhD
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Journal of Patient Experience
Online Access:https://doi.org/10.1177/23743735251331770
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemoradiotherapy treatment for glioblastoma causes acute and long-term toxicities, negatively impacting quality of life. Patients require evidence-based, yet understandable information regarding treatment-induced toxicities to increase preparedness for treatment. A repeat cross-sectional, qualitative design was used. Semi-structured interviews were conducted with glioblastoma patients and their caregivers at set timepoints: prior to (T1), during (T2), and post (T3) chemoradiotherapy. Interviews were recorded, transcribed verbatim, and thematically analyzed. In total, 19 patients and 12 caregivers were interviewed. Three main themes emerged. (1) Navigating information materials, (2) Lack of awareness and understanding of chemoradiotherapy-induced toxicities, (3) The actual experience and impact of chemoradiotherapy toxicities. There is a discrepancy between the treatment information materials provided and patient expectation and experience of toxicities during and after chemoradiotherapy. Current informational resources do not adequately prepare patients or caregivers for the reality of treatment-induced toxicities. Better tailored resources are needed as individual needs fluctuate across the treatment trajectory. Further cross-center investigation is required to understand how we best create a personalized information pathway for glioma patients.
ISSN:2374-3743